| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 9
| Issue : 1 | Page : 1-4 |
|
|
Advances in clinical concept of retinopathy of prematurity treatment
Amir Ahmadzadeh-Amiri1, Ahmad Ahmadzadeh-Amiri2
1 Department of Eye, Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Eye, Bu Ali-Sina Hospital, Medical Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran
Correspondence Address:
Ahmad Ahmadzadeh-Amiri
Department of Eye, Bu Ali-Sina Hospital, Medical Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/sjopthal.sjopthal_8_17
|
|
|
Retinopathy of prematurity (ROP) continues a major cause of premature infants' blindness and rises the incidence with improved survival of very premature infants. Timely screening for ROP risk and treatment is important to retain visual rehabilitation. Recent advance in genetic studies shows a Wnt pathway ROP linking genes predispose to the evolution of severe ROP. A newly screening method is recommended based on weight gain postnatally in combination with insulin-like growth factor levels for prediction of ROP risk. Anti-vascular endothelial growth factor treatment options for severe cases of ROP have been showed safe in preterm infants. However, several studies suggest that early laser therapy for Type 1 but not Type 2 high-risk ROP makes better visual results. This review gives an outline of the recent advances on ROP with treatment options and screening methods.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
